IGF-1 LR3

Long [Arg3]-IGF-I, commonly called IGF-1 LR3, adds a 13-residue N-terminal extension to the 70-residue IGF-I sequence and substitutes arginine for glutamic acid at position 3. The original recombinant-analogue study describes its altered interactions with IGF-binding proteins.

The INCRELEX label concerns mecasermin, whose 70-amino-acid sequence matches endogenous human IGF-I. Its approval for particular pediatric growth-failure conditions does not establish approval, dose, handling or safety of LR3.

In the 1992 experiments, LR3 was more potent than authentic IGF-I on several measures in cell systems that secreted binding proteins. In chicken embryo fibroblasts without detectable binding-protein secretion, LR3 was less potent. The context-dependent findings do not support a universal potency multiplier.

Growth hormone stimulates IGF-I production; it is not chemically converted into IGF-I. Reduced binding-protein interaction cannot by itself establish a longer human half-life, superior delivery to trained muscle or an all-day clinical effect.

A dexamethasone-treated rat experiment found anabolic effects on weight, nitrogen retention and protein turnover, with LR3 more potent than native IGF-I in that catabolic model. These findings support research into growth-factor biology.

They do not establish that healthy adults will gain 5–15 pounds of retained muscle, increase strength within two weeks, heal joints or improve skin. Cell proliferation, rat nitrogen balance and human strength are different outcomes. Personal training reports remain anecdotes unless the product, concurrent interventions and outcome are adequately evaluated.

The cited LR3 studies do not validate a 40–100 microgram daily injection schedule, a two-injection split, five-days-on/two-days-off cycling or a training-specific titration rule. The mecasermin prescribing label applies to a different molecule and diagnosed pediatric conditions; its instructions cannot be repurposed as an LR3 bodybuilding protocol.

No universal diluent, vial stability period or combination schedule follows from the LR3 name. Proposed stacks with growth-hormone secretagogues, follistatin or MGF require their own efficacy and interaction evidence.

The original cell study and rat catabolism study provide direct LR3 evidence. Broad statements about native IGF-I treatment cannot be substituted for LR3 clinical outcomes.

A 2021 analytical study administered LR3 intramuscularly to rats and tested degradation in human blood outside the body. Unchanged LR3 was detectable for a shorter period than some related analogues; a metabolite lasted longer. Detection windows are not human elimination half-lives and do not verify the often-repeated 20–30-hour value.

The current mecasermin label warns of severe hypoglycemia, including seizures, and includes other important contraindications and warnings. This demonstrates why IGF signaling should not be described as inherently harmless, but mecasermin event rates and management instructions are not measured LR3 safety data.

LR3’s long-term human, reproductive, interaction and cancer-related risks are not resolved by the cited studies. A proliferative mechanism neither proves clinical cancer causation nor establishes safety. The analytical study also found oxidized forms in tested black-market products; those observations cannot certify a different vial.

LR3 is a useful growth-factor research analogue with genuine biological activity and encouraging anabolic findings in specific experimental systems. The binding-protein work helps explain that activity. A clinically validated performance protocol, dependable human muscle-gain forecast and safe long-term stack remain different questions.

Editorial update: October 27, 2026. Original LR3 cell/rat/detection abstracts and the relevant current mecasermin label sections were checked; the prior accepted comparison’s source work was reused. Not all full papers were obtained. US LR3 product status is left unassessed in the explorer rather than inferred from the different mecasermin label. This editorial source check has not received clinician review. Related guides and comparisons may have different review dates. Read a key primary source.